| Literature DB >> 35680259 |
Runhua Zhang1,2, Gaifen Liu2,3, Yuesong Pan2,3, Maigeng Zhou4, Yongjun Wang5,3.
Abstract
OBJECTIVES: There is uncertainty with respect to the hospital volume and clinical outcomes for patients with stroke. This study aimed to assess the association between hospital volume, processes of care and outcomes after ischaemic stroke.Entities:
Keywords: adult neurology; neurology; stroke
Mesh:
Year: 2022 PMID: 35680259 PMCID: PMC9185595 DOI: 10.1136/bmjopen-2021-060015
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1The flow chart for patient selection.
Hospital and patient characteristics by quartiles of hospital volume
| Characteristic | Total | Q1 hospitals | Q2 hospitals | Q3 hospitals | Q4 hospitals | P value | P for trend |
|
| |||||||
| Number of hospitals | 217 | 53 | 56 | 53 | 55 | ||
| Teaching hospital | 125 (57.6%) | 23 (43.4%) | 23 (41.1%) | 37 (69.8%) | 42 (76.4%) | <0.0001 | <0.0001 |
| Stroke unit | 121 (55.8%) | 24 (45.3%) | 24 (42.9%) | 35 (66%) | 38 (69.1%) | 0.0062 | 0.0017 |
| Beds | 1000 (600–1650) | 600 (500–800) | 780 (515–1000) | 1300 (1000–2000) | 1500 (1200–2200) | <0.0001 | <0.0001 |
| Geographical region | |||||||
| East | 121 (55.8%) | 29 (54.7%) | 35 (62.5%) | 28 (52.8%) | 29 (52.7%) | 0.6967 | <0.0001 |
| Middle | 66 (30.4%) | 15 (28.3%) | 13 (23.2%) | 20 (37.7%) | 18 (32.7%) | ||
| West | 30 (13.8%) | 9 (17%) | 8 (14.3%) | 5 (9.4%) | 8 (14.5%) | ||
|
| |||||||
| Male | 11 163 (63.6%) | 2126 (63.1%) | 3349 (62.2%) | 2108 (64.2%) | 3580 (64.9%) | 0.0183 | 0.0085 |
| Age | 65 (57-74) | 66 (57-75) | 65 (57-74) | 66 (58-74) | 64 (55-73) | <0.0001 | <0.0001 |
| Health insurance | |||||||
| URBMI | 8959 (51%) | 1715 (50.9%) | 2552 (47.4%) | 1568 (47.8%) | 3124 (56.7%) | <0.0001 | <0.0001 |
| NRCMS | 6932 (39.5%) | 1369 (40.6%) | 2440 (45.3%) | 1394 (42.5%) | 1729 (31.4%) | ||
| Commercial insurance | 60 (0.3%) | 8 (0.2%) | 27 (0.5%) | 4 (0.1%) | 21 (0.4%) | ||
| Self-payment | 1599 (9.1%) | 279 (8.3%) | 367 (6.8%) | 315 (9.6%) | 638 (11.6%) | ||
| Education | |||||||
| Elementary or below | 7934 (45.2%) | 1693 (50.2%) | 2430 (45.1%) | 1678 (51.1%) | 2133 (38.7%) | <0.0001 | <0.0001 |
| Middle school | 4109 (23.4%) | 715 (21.2%) | 1286 (23.9%) | 661 (20.1%) | 1447 (26.3%) | ||
| High school or above | 5507 (31.4%) | 963 (28.6%) | 1670 (31%) | 942 (28.7%) | 1932 (35.1%) | ||
| Previous or current smoking | 7818 (44.5%) | 1457 (43.2%) | 2406 (44.7%) | 1455 (44.3%) | 2500 (45.4%) | 0.2676 | 0.0836 |
| Drinking | 5277 (30.1%) | 872 (25.9%) | 1681 (31.2%) | 995 (30.3%) | 1729 (31.4%) | <0.0001 | 0.0001 |
| Medical history | |||||||
| Hypertension | 11 386 (64.9%) | 2156 (64%) | 3511 (65.2%) | 2136 (65.1%) | 3583 (65%) | 0.6614 | 0.459 |
| Diabetes | 3630 (20.7%) | 658 (19.5%) | 1097 (20.4%) | 673 (20.5%) | 1202 (21.8%) | 0.0599 | 0.0086 |
| Hyperlipidaemia | 2128 (12.1%) | 372 (11%) | 808 (15%) | 384 (11.7%) | 564 (10.2%) | <0.0001 | 0.0001 |
| Atrial fibrillation | 1185 (6.8%) | 212 (6.3%) | 402 (7.5%) | 280 (8.5%) | 291 (5.3%) | 0.0001 | 0.0174 |
| Stroke or TIA | 5918 (33.7%) | 1084 (32.2%) | 1886 (35%) | 1113 (33.9%) | 1835 (33.3%) | 0.0411 | 0.8641 |
| Medication history | |||||||
| Antiplatelet | 3444 (19.6%) | 599 (17.8%) | 1008 (18.7%) | 712 (21.7%) | 1125 (20.4%) | <0.0001 | 0.0002 |
| Anticoagulation | 178 (1%) | 33 (1%) | 69 (1.3%) | 35 (1.1%) | 41 (0.7%) | 0.0467 | 0.0696 |
| Antihypertension | 7868 (44.8%) | 1454 (43.1%) | 2592 (48.1%) | 1401 (42.7%) | 2421 (43.9%) | <0.0001 | 0.1248 |
| Lipid-lowering medicine | 1207 (6.9%) | 195 (5.8%) | 487 (9%) | 241 (7.3%) | 284 (5.2%) | <0.0001 | 0.0002 |
| Antidiabetics | 2782 (15.9%) | 500 (14.8%) | 875 (16.2%) | 509 (15.5%) | 898 (16.3%) | 0.2276 | 0.1842 |
| NIHSS at admission | 4 (2–7) | 4 (2–7) | 4 (2–6) | 4 (2–8) | 4 (2–7) | <0.0001 | <0.0001 |
| Days of hospitalisation | 13 (9–16) | 13 (10–16) | 13 (9–15) | 13 (9–16) | 13 (10–16) | <0.0001 | 0.0211 |
NIHSS, National Institutes of Health Stroke Scale; NRCMS, new rural cooperative medical scheme; TIA, transient ischaemic attack; URBMI, urban resident basic medical insurance.
The rates of achievement in process measures
| Process measures | Total | Q1 hospitals | Q2 hospitals | Q3 hospitals | Q4 hospitals |
| rt-PA | 217/1303 (16.7) | 36/250 (14.4) | 75/497 (15.1) | 25/200 (12.5) | 81/356 (22.8) |
| Early antithrombotic | 14 555/17 243 (84.4) | 2802/3303 (84.8) | 4508/5307 (84.9) | 2903/3199 (90.7) | 4342/5434 (79.9) |
| Dysphagia screening | 14 876/17 550 (84.8) | 2630/3371 (78.0) | 4860/5386 (90.2) | 2615/3281 (79.7) | 4771/5512 (86.6) |
| DVT prophylaxis | 3367/5079 (66.3) | 630/944 (66.7) | 1006/1481 (67.9) | 689/914 (75.4) | 1042/1740 (59.9) |
| Antithrombotic medication | 14 722/16 002 (92) | 2845/3058 (93.0) | 4481/4765 (94.0) | 2839/3089 (91.9) | 4557/5090 (89.5) |
| Lowering LDL-C medication | 7700/11 597 (66.4) | 1436/2247 (63.9) | 2591/3621 (71.6) | 1523/2120 (71.8) | 2150/3609 (59.6) |
| Antihypertensive medication for hypertension | 8867/13 385 (66.2) | 1712/2611 (65.6) | 2764/4207 (65.7) | 1710/2470 (69.2) | 2681/4097 (65.4) |
| Hypoglycaemic medication for diabetes | 3662/4898 (74.8) | 685/907 (75.5) | 1114/1494 (74.6) | 721/901 (80.0) | 1142/1596 (71.6) |
| Anticoagulation for AF | 303/1437 (21.1) | 43/278 (15.5) | 86/468 (18.4) | 87/325 (26.8) | 87/366 (23.8) |
| Smoking cessation | 6712/7819 (85.8) | 1227/1457 (84.2) | 2098/2406 (87.2) | 1213/1456 (83.3) | 2174/2500 (87.0) |
| Defect-free measure of care | 5816/17 550 (33.1) | 992/3371 (29.4) | 1965/5386 (36.5) | 1150/3281 (35.1) | 1709/5512 (31.0) |
N1 indicates the number of patients who received the process of care, and N2 indicates the number of patients eligible.
AF, atrial fibrillation; DVT, deep vein thrombosis; LDL-C, low-density lipoprotein cholesterol; rt-PA, recombinant tissue plasminogen activator.
The association between hospital volume and process measures
| Performance measures | Q1 vs Q4 | Q2 vs Q4 | Q3 vs Q4 | |||
| Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | |
| rt-PA | 1.54 (0.61 to 3.89) | 0.3614 | 1.46 (0.68 to 3.14) | 0.3343 | 0.71 (0.35 to 1.48) | 0.3634 |
| Early antithrombotic | 0.68 (0.20 to 2.32) | 0.5364 | 1.17 (0.30 to 4.55) | 0.8245 | 1.07 (0.36 to 3.18) | 0.9020 |
| Dysphagia screening | 0.76 (0.33 to 1.74) | 0.5104 | 2.19 (0.86 to 5.55) | 0.0987 | 0.90 (0.42 to 1.92) | 0.7845 |
| DVT prophylaxis | 1.02 (0.52 to 2.01) | 0.9504 | 1.09 (0.57 to 2.09) | 0.7936 | 1.55 (0.84 to 2.83) | 0.1594 |
| Antithrombotic medication | 1.26 (0.61 to 2.61) | 0.5391 | 1.27 (0.61 to 2.64) | 0.5277 | 1.16 (0.63 to 2.15) | 0.6375 |
| Lowering LDL-C medication | 0.92 (0.57 to 1.50) | 0.7460 | 1.03 (0.62 to 1.70) | 0.9224 | 1.20 (0.78 to 1.84) | 0.4134 |
| Antihypertensive medication for hypertension | 0.99 (0.71 to 1.38) | 0.9395 | 0.92 (0.67 to 1.27) | 0.6152 | 1.11 (0.81 to 1.53) | 0.5041 |
| Hypoglycaemic medication for diabetes | 1.02 (0.67 to 1.55) | 0.9210 | 1.06 (0.69 to 1.65) | 0.7818 | 0.97 (0.65 to 1.46) | 0.8888 |
| Anticoagulation for AF | 0.63 (0.34 to 1.16) | 0.1365 | 0.87 (0.53 to 1.44) | 0.5848 | 1.05 (0.61 to 1.78) | 0.8681 |
| Smoking cessation | 0.56 (0.10 to 2.97) | 0.4939 | 0.67 (0.12 to 3.63) | 0.6421 | 2.08 (0.25 to 17.2) | 0.4961 |
| Defect-free measure of care | 0.93 (0.61 to 1.42) | 0.7412 | 1.25 (0.85 to 1.85) | 0.2634 | 1.11 (0.76 to 1.63) | 0.5853 |
AF, atrial fibrillation; DVT, deep vein thrombosis; LDL-C, low-density lipoprotein cholesterol; rt-PA, recombinant tissue plasminogen activator.
Figure 2The Kaplan-Meier curve for mortality (A) and recurrent stroke (B) within 1 year.
The rates of clinical outcomes according to quartiles of hospital volume
| Outcome | Q1 | Q2 | Q3 | Q4 | P value |
| 3 months | |||||
| Mortality, no (%) | 167 (4.95) | 196 (3.64) | 142 (4.33) | 187 (3.39) | 0.0011 |
| Poor outcome, no (%)* | 783 (23.41) | 1042 (19.51) | 698 (21.37) | 1160 (21.15) | 0.0003 |
| Stroke recurrence, no (%) | 178 (5.28) | 297 (5.51) | 166 (5.06) | 238 (4.32) | 0.0298 |
| Combined vascular events, no (%) | 183 (5.43) | 303 (5.63) | 168 (5.12) | 247 (4.48) | 0.0440 |
| 1 year | |||||
| Mortality, no (%) | 306 (9.59) | 393 (7.69) | 256 (8.39) | 367 (7.16) | 0.0006 |
| Poor outcome, no (%)† | 817 (25.69) | 1058 (20.71) | 665 (21.81) | 1161 (22.65) | <0.0001 |
| Stroke recurrence, no (%) | 228 (7.15) | 388 (7.59) | 209 (6.85) | 327 (6.38) | 0.1121 |
| Combined vascular events, no (%) | 236 (7.40) | 406 (7.94) | 216 (7.08) | 368 (7.18) | 0.3986 |
*A total of 17 438 patients achieved modified Rankin Scale at 3 months.
†A total of 16 462 patients achieved modified Rankin Scale at 1 year.
The association between hospital volume and clinical outcomes
| Outcome | Q1 vs Q4 | Q2 vs Q4 | Q3 vs Q4 | |||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
|
| ||||||
| Mortality | ||||||
| Unadjusted | 1.54 (1.13 to 2.09) | 0.0059 | 1.09 (0.85 to 1.40) | 0.4772 | 1.26 (0.89 to 1.79) | 0.1861 |
| Adjusted | 1.27 (0.88 to 1.83) | 0.2062 | 0.99 (0.75 to 1.30) | 0.9179 | 1.18 (0.82 to 1.68) | 0.3708 |
| Poor outcome | ||||||
| Unadjusted | 1.22 (1.01 to 1.47) | 0.0377 | 0.95 (0.81 to 1.11) | 0.5341 | 1.06 (0.89 to 1.26) | 0.4937 |
| Adjusted | 1.17 (0.91 to 1.52) | 0.2269 | 0.95 (0.74 to 1.22) | 0.6891 | 0.96 (0.75 to 1.22) | 0.7185 |
| Recurrent stroke | ||||||
| Unadjusted | 1.27 (0.92 to 1.75) | 0.1403 | 1.21 (0.91 to 1.61) | 0.1992 | 1.16 (0.85 to 1.58) | 0.3563 |
| Adjusted | 1.16 (0.83 to 1.62) | 0.3798 | 1.11 (0.79 to 1.56) | 0.5474 | 1.11 (0.78 to 1.56) | 0.5620 |
| Combined vascular events | ||||||
| Unadjusted | 1.27 (0.92 to 1.76) | 0.1391 | 1.19 (0.89 to 1.60) | 0.2437 | 1.14 (0.83 to 1.56) | 0.4304 |
| Adjusted | 1.15 (0.82 to 1.61) | 0.4109 | 1.09 (0.78 to 1.53) | 0.6167 | 1.08 (0.76 to 1.52) | 0.6763 |
|
| ||||||
| Mortality | ||||||
| Unadjusted | 1.48 (1.17 to 1.88) | 0.0013 | 1.13 (0.93 to 1.38) | 0.2097 | 1.22 (0.96 to 1.54) | 0.0996 |
| Adjusted | 1.15 (0.89 to 1.47) | 0.2829 | 0.98 (0.79 to 1.22) | 0.8663 | 1.05 (0.82 to 1.35) | 0.6743 |
| Poor outcome | ||||||
| Unadjusted | 1.29 (1.08 to 1.54) | 0.0043 | 0.94 (0.81 to 1.09) | 0.4317 | 1.00 (0.86 to 1.17) | 0.9917 |
| Adjusted | 1.29 (1.01 to 1.64) | 0.0393 | 0.98 (0.78 to 1.24) | 0.8758 | 0.85 (0.68 to 1.06) | 0.1566 |
| Recurrent stroke | ||||||
| Unadjusted | 1.20 (0.91 to 1.59) | 0.1939 | 1.18 (0.93 to 1.49) | 0.1853 | 1.08 (0.83 to 1.40) | 0.5552 |
| Adjusted | 1.08 (0.81 to 1.43) | 0.6025 | 1.05 (0.80 to 1.37) | 0.7277 | 1.01 (0.77 to 1.32) | 0.9491 |
| Combined vascular events | ||||||
| Unadjusted | 1.11 (0.84 to 1.45) | 0.4583 | 1.10 (0.87 to 1.39) | 0.4307 | 1.00 (0.77 to 1.30) | 0.9906 |
| Adjusted | 0.97 (0.75 to 1.27) | 0.8487 | 0.96 (0.75 to 1.24) | 0.7727 | 0.92 (0.71 to 1.19) | 0.5181 |
The adjusted covariates included age, sex, health insurance (urban resident basic medical insurance, new rural cooperative medical scheme, commercial insurance, self-payment), education (elementary or below, middle school, high school or above), previous or current smoking, drinking, comorbidities (hypertension, diabetes, hyperlipidaemia, atrial fibrillation, history of stroke), NIHSS at admission, hospital characteristics (academic status, beds, stroke unit and location) and the composite measure of care.
NIHSS, National Institutes of Health Stroke Scale.
Figure 3Association between hospital stroke volume and all-cause mortality. (A) Hospital volume and 3-month all-cause mortality. (B) Hospital volume and 1-year all-cause mortality. The reference point is the median value of hospital volume (476 annual stroke discharges) in all patients.